Our Team

Our studio was forged in 2021 by – Max, Michel, and Sriram – united by their shared goal to re-establish discovery as the basis for the next generation of immunotherapies.

With their deep knowledge of immunobiology and their impressive track record of discovering and developing multiple, multibillion-dollar immunotherapies, they have positioned Foundery to increase the efficiency and effectiveness of the pre-clinical R&D process.

They aim to preserve the innovative culture of biotech and bridge the translational gap by providing leading academic scientists with exclusive access to best-in-class technology platforms and the necessary R&D infrastructure to transform their discoveries into breakthrough therapies.

Executive Management Team

A Proven Record of Selecting and Developing Commercially Successful Therapies

Photo of Max Krummel

Max Krummel, PhD

Founder &
Managing Member
  • UCSF Professor & Endowed Chair in Experimental Pathology
  • Discovered and patented Checkpoint Blockade Target CTLA-4 (2022 Yervoy® Sales: $2B)
  • Defined Myeloid Tuning & founded Pionyr (Gilead secured $1.7B Buyout Option in 2020)
  • Discovered Immune Archetypes in Cancer & COVID
  • PhD, University California, Berkeley
View full bio
Photo of Michel Streuli

Michel Streuli, PhD

Founder, Managing Member, &
Chief Executive Officer
  • Drove early development of multiple immunotherapies, including IntronA and Keytruda® (2022 Keytruda® Sales: $21B)
  • 20+ year biotech veteran
  • Former Professor at Harvard and Dana-Farber Cancer Institute
  • PhD, University of Zurich
View full bio
Photo of Venkataraman "Sriram"

Venkataraman “Sriram”, PhD

Founder, Managing Member, &
Chief Scientific Officer
  • Guided preclinical pharmacology for Keytruda® and led Pionyr’s non-clinical PY314 program
  • 15+ years experience in immuno-oncology R&D and strategy development at Schering-Plough, Merck, Gilead and Pionyr
  • Expertise in small molecule and biologics development for immuno-oncology
  • PhD, University of Madras
View full bio
Photo of Jate Samathivathanachai

Jate Sam, MBA, CLP

Chief Business
  • Executed >$10B in M&A, financing, licensing transactions and ~$70M in PE/VC investments
  • 20 years of investment banking, corporate development, principal investing and general management experience in the biopharma and consumer sectors
  • MBA, Kellogg School of Management, Northwestern University
  • Certified Licensing Professional
View full bio

Operating Team and Studio

Team’s Deep Experience Enables Translation of Academic Discoveries into High-value Preclinical Therapies

Photo of Elizabeth Edmiston

Elizabeth Edmiston, PhD

Senior Director, Business Operations & Investor Relations
  • 7 Years Academic and Industry Experience
  • Prior Position: Senior Alliance and Business Development Manager, UCSF
  • PhD, Immunology, University of California, Davis
View full bio
Photo of Joshua Pollack

Joshua Pollack, MS

Senior Director, Bioinformatics
  • 14 Years Academic and Industry Experience
  • Prior Position: Associate Director, Bioinformatics & Trans. Biology, Pionyr
  • MS, Computational Biology and Genomics, University of California, Berkeley
View full bio
Photo of Vladi Juric

Vladi Juric, PhD

Senior Director, Pharmacology
  • 13 Years Academic and Industry Experience
  • Prior Position: Director, Early Discovery Biology, Pionyr
  • PhD, Biochemistry and Molecular Genetics, University of Illinois, Chicago
View full bio
Map of the Foundery headquarters near the UCSF campus

Foundery Headquarters

  • Our 350 Parnassus location provides unprecedented physical proximity to cutting-edge immunologists
  • 13,600 square feet of laboratory and office space
  • Designed to accommodate a 1-2 NewCos

Scientific Advisory Board

An Amalgam of Cutting-edge Scientists Collectively Providing Wide-ranging Scientific and Technical Expertise and External R&D Review

Ananda Goldrath

Ananda Goldrath, PhD

Tata Chancellor’s Endowed Professor, Molecular Biology, UC San Diego
T Cell KOL
View full bio
Dan Littman

Dan Littman, MD, PhD

Helen L. and Martin S. Kimmel Professor of Molecular Immunology, NYU School of Medicine
Integrated Immune KOL
View full bio
Rich Locksley

Richard Locksley, MD

Marion and Herbert Sandler Distinguished Professor, UC San Francisco
Innate Lymphocyte Biology KOL
View full bio
Alexis Combes

Alexis Combes, PhD

Associate Professor, Pathology, UC San Francisco
Immune Archetype KOL
View full bio
Leonard Presta

Leonard G. Presta, PhD

Retired Biotech Veteran
Renowned Antibody & Protein Engineer
View full bio
Adil Daud

Adil Daud, MD

Director of Melanoma Clinical Research, Helen Diller Family Comprehensive Cancer Center, UC San Francisco
Immunotherapy KOL
View full bio

Contact Us

Interested in learning more? We're looking forward to hearing from you.